Arbutus Biopharma Corp Cash and Cash Equivalents, Fair Value Disclosure
Arbutus Biopharma Corp (ABUS) had Cash and Cash Equivalents, Fair Value Disclosure of $18.01 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-03-23
- 2012-12-31: Cash and Cash Equivalents, Fair Value Disclosure 44.15M CAD.
- 2011-12-31: Cash and Cash Equivalents, Fair Value Disclosure 1.56M CAD.
CAD
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2012-12-31 | 44.15M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 1.56M CAD 20-F · filed 2013-03-27 |
USD
| Period end | Cash and Cash Equivalents, Fair Value Disclosure | Cash and Cash Equivalents, Fair Value Disclosure as first filed |
|---|---|---|
| 2025-12-31 | $18.01M 10-K · filed 2026-03-23 | |
| 2024-12-31 | $36.33M 10-K · filed 2026-03-23 | |
| 2018-03-31 | $12.46M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $54.29M 10-Q · filed 2018-05-04 | |
| 2017-09-30 | $15.22M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $24.21M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $29.85M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $23.41M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $26.63M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $42.97M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $144.77M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $166.78M 10-K · filed 2017-03-22 | |
| 2015-09-30 | $181.09M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $207.21M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $232.28M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $72.19M 10-K · filed 2016-03-09 | |
| 2014-09-30 | $78.18M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $85.27M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $134.36M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $68.72M 10-K · filed 2015-03-13 | $68.72M 6-K · filed 2014-03-06 |
| 2012-12-31 | $44.37M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |